Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 Infusions in Familial HDL-c Deficiency
2011-006188-23Phase 2Active
- Sponsor
- ABIONYX Pharma
- Start
- Dec 2011
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of CER-001 in Familial high-density lipoprotein deficiency (FHD) and hypercholesterolemia, sponsored by ABIONYX Pharma. Primary endpoints: Percent change in carotid total vessel area (TVA) and Percent change in normalized wall index (NWI). Started Dec 2011; status: active.
02
Drugs
CER-001
03
Conditions
Familial high-density lipoprotein deficiency (FHD)hypercholesterolemia
Beyond the preview
Go deeper on 2011-006188-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006188-23.